The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
PET/MR in Dementia and Other Neurodegenerative Diseases
Abstract
The spectrum of neurodegenerative diseases covers the dementias, parkinsonian syndromes, Huntington disease, amyotrophic lateral sclerosis, and prion diseases. In these entities, brain MRI is often used in clinical routine to exclude other pathologies and to demonstrate specific atrophy patterns. [18F]FDG PET delivers early and sensitive readouts of neural tissue loss, and more specific PET tracers currently in use clinically target β-amyloid plaques or dopaminergic deficiency. The recent integration of PET into MR technology offers a new chance to improve early and differential diagnosis of many neurodegenerative diseases. Initial evidence in the literature is available to support this notion. New emerging PET tracers, such as tracers that bind to tau or α-synuclein aggregates, as well as MR techniques, like diffusion-tensor imaging, resting-state functional MRI, and arterial spin labeling, have the potential to broaden the diagnostic capabilities of combined PET/MRI to image dementias, Parkinson disease, and other neurodegenerative diseases. The ultimate goal is to establish combined PET/MRI as a first-line imaging technique to provide, in a one-stop-shop fashion with improved patient comfort, all biomarker information required to increase diagnostic confidence toward specific diagnoses. The technical challenge of accurate PET data attenuation correction within PET/MRI systems needs yet to be solved. Apart from the projected clinical routine applications, future research would need to answer the questions of whether combined brain PET/MRI is able to improve basic research of neurodegenerative diseases and antineurodegeneration drug testing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Diagnosis of neurodegenerative diseases is usually based on subjective cognitive tests in combination with neuroimaging [131–133], but the current techniques are not able to successfully diagnose these diseases in their earlier stages, when the pathology is already present but does not cause symptoms yet.”
From Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation (2019) · cites this paper as [131]
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“This led to the stratification of 33%, 48%, and 19% of the MCI subjects as unlikely owing to AD, intermediate, and high likelihood of MCI due to AD, respectively, according to established diagnostic criteria.(19) For the remaining 41 patients with AD dementia, 59% had pathologic PET and 44%had pathologic PETþMR images.”
Albert, M., DeKosky, S. T., Dickson, D. W., Dubois, B., Feldman, H., Fox, N. C., Gamst, A. C., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.11.1.96 · Cited by 2,643
Simultaneous PET-MRI: a new approach for functional and morphological imaging
Judenhofer, M. S., Wehrl, H. F., Newport, D. F., Catana, C., Siegel, S. B., Becker, M., Thielscher, A., Kneilling, M., Lichy, M. P., Eichner, M., et al. (2008) · Nature Medicine · doi:10.1038/nm1700 · Cited by 983
Simultaneous MR/PET Imaging of the Human Brain: Feasibility Study
Schlemmer, H.-P., Pichler, B. J., Schmand, M. J., Burbar, Z., Michel, C. J., Ladebeck, R., Jattke, K., Townsend, D. W., Nahmias, C., Jacob, P. K., et al. (2008) · Radiology · doi:10.1148/radiol.2483071927 · Cited by 473
Molecular Basis of the Neurodegenerative Disorders
Martin, J. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906243402507 · Cited by 422
Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.120618 · Cited by 329
In Vivo Quantitative Susceptibility Mapping (QSM) in Alzheimer's Disease
Acosta‐Cabronero, J., Williams, G. B., Cárdenas‐Blanco, A., Arnold, R. J., Lupson, V. C., & Nestor, P. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081093 · Cited by 302
PET/MRI for Neurologic Applications
Catana, C., Drzezga, A. E., Heiss, W., & Rosen, B. R. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.105346 · Cited by 292
Riedl, V., Kurcyus, K., Strobel, C., Tahmasian, M., Grimmer, T., Förster, S., Friston, K. J., Sorg, C., & Drzezga, A. E. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0492-14.2014 · Cited by 193
Cited by
Sorted by citations
Items 101–123 of 123
Páez, D., Mariani, G., Pascual, T. N. B., & Kashyap, R. K. (2016) · Springer eBooks · doi:10.1007/978-3-319-31614-7_19
Nuclear Imaging of Movement Disorders
Tatsch, K. (2016) · Springer eBooks · doi:10.1007/978-3-319-30081-8_27
Neuroimaging and Treatments Perspectives
Hoffmann, M. W. (2016) · Springer eBooks · doi:10.1007/978-3-319-33181-2_13
Hybrid PET/MR: Updated Clinical Use and Potential Applications
Nunes, R. F., Barbosa, F. D. G., & Queiroz, M. A. (2016) · Current Radiology Reports · doi:10.1007/s40134-016-0191-7
MR-Based Attenuation Correction in Brain PET/MR Studies: A Short Review
Giovannini, E., Giovacchini, G., Nicolosi, S., Riondato, M., & Ciarmiello, A. (2017) · Journal of Diagnostic Imaging in Therapy · doi:10.17229/jdit.2017-0410-028
Brain PET in the Evaluation of Cognitive Function and Dysfunction
Kirsch, D. E., Visnagra, K. M., & Silverman, D. H. S. (2017) · Internal Medicine Review · doi:10.18103/imr.v3i6.466
Beyer, L., & Rominger, A. (2018) · Der Nuklearmediziner · doi:10.1055/a-0621-3227
Anisotropia fracionada na substância negra não é um biomarcador diagnóstico para doença de Parkinson
Hirata, F. D. C. C. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2019.tde-15012019-102222
Ando, T., Kemp, B. J., Warnock, G., Sekine, T., Kaushik, S. S., Wiesinger, F., & Delso, G. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.569706
Wimalarathne, D. D. N., Ruan, W., Sun, X., Liu, F., Hu, F., & Lan, X. (2021) · Research Square · doi:10.21203/rs.3.rs-439974/v1
Kritikos, M., & Clouston, S. (2021) · Springer eBooks · doi:10.1007/978-3-030-82367-2_5
Sathekge, M. M., & Bouchelouche, K. (2026) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2026.04.008
Differential diagnosis of dementia in idiopathic normotensive hydrocephalus
Fala, P., Gavriliuc, P., Andronachi, V., Andrușca, A., & Gavriliuc, O. (2022) · Bulletin of the Academy of Sciences of Moldova Medical Sciences · doi:10.52692/1857-0011.2021.3-71.26
Seok-Hwan, Y., Jang, J. S., & Park, C. (2022) · Journal of the Korean Physical Society · doi:10.1007/s40042-022-00522-x
Leporace, M., Calabria, F. F., Gaudio, E., Schillaci, O., Ciaccio, A., & Bagnato, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90454-4.00006-9
Evidenced-based biological prevention and intervention strategies of dementia: a narrative review
Abukuri, D. N. (2023) · Current Psychology · doi:10.1007/s12144-023-05017-x
Calabria, F. F., Cimini, A., Bagnato, A., Gullà, D., Cascini, G. L., Urbano, N., & Schillaci, O. (2024) · Springer eBooks · doi:10.1007/978-3-031-54196-4_1
Advances in Medical Imaging Equipment: A Review of Research Progress and Clinical Applications
Ding, Q. (2025) · Highlights in Science Engineering and Technology · doi:10.54097/j70wkr50
18F-FDG PET for Neurodegenerative Diseases: Principles and Progress
Thientunyakit, T., Wannasoupol, N., Sethanandha, C., Piyapittayanan, S., Siriprapa, T., Thongpraparn, T., Muangpaisan, W., & Gelovani, J. G. (2025) · Neuromethods · doi:10.1007/978-1-0716-4494-2_6
Mannheim, J. G., Cheng, J.-C. (., Vafai, N. M., Shahinfard, E., English, C., McKenzie, J., Zhang, J., Barlow, L., & Sossi, V. (2021) · Figshare · doi:10.6084/m9.figshare.14129408
Vers l'imagerie in vivo de l'alpha-synucléine.
Levigoureux, E. (2015) · doi:10.70675/324ece83z7656z4606z86eez1a097ae9a567
The trajectory of PET/MRI: from technical proof of concept to domain-specific precision imaging
Asmundo, L., Harrington, S. G., Kako, B., Queiroz, M. A., Cañamaque, L. G., Field, C. A., & Vanzulli, A. (2026) · Clinical and Translational Imaging · doi:10.1007/s40336-026-00804-5
Metadata
- Authors
- Barthel, H., Schroeter, M. L., Hoffmann, K.-T., & Sabri, O.
- Affiliations
- University Hospital Leipzig (DE)
- Max Planck Institute for Human Cognitive and Brain Sciences (DE)
- Leipzig University (DE)
- Corresponding author
- Barthel, Henryk
- Venue
- Seminars in Nuclear Medicine
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 45
- Issue
- 3
- Pages
- 224-233
- ISSN
- 0001-2998 (ISSN-L)
- OpenAlex
- W1987273610
- Cited by
- 123
- References
- 26
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 10 · 2023: 6 · 2022: 10 · 2021: 12 · 2020: 7 · 2019: 12 · 2018: 16 · 2017: 13 · 2016: 20 · 2015: 5
- FWCI
- 14.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Seminars in Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
- Keywords
- PET/MRI, neurodegenerative diseases, dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, FDG-PET, amyloid PET tracers, tau PET tracers, diffusion tensor imaging, resting-state fMRI, arterial spin labeling, PET attenuation correction, neurodegeneration biomarkers, differential diagnosis
- MeSH terms
- Dementia, Humans, Magnetic Resonance Imaging, Parkinsonian Disorders, Positron-Emission Tomography, Multimodal Imaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
